Pay in 4 interest-free payments of $7.18 Learn more
Ships within 48 hours · Estimated delivery Oct 18 - Oct 23
Individuals with T2DM frequently have multiple cardiovascular risk factors, including obesity (32.9%), hypertension (32-80%), and dyslipidemia (39%) ( The association between glycemic control and cardiovascular outcomes in DM patients has been long studied ( To address these challenges, novel pharmacological therapies such as sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged, offering cardioprotective benefits ( The aim of this review is to enhance our understanding of the role of SGLT-2i and GLP-1 RAs in managing patients with T2DM and CVD
For example, in cancer, combining HSP90 inhibitors with autophagy inhibitors could lead to the accumulation of misfolded proteins and induce cell death
However, if this compensation is inadequate, blood glucose levels increase and eventually diabetes develops
Symptoms include shakiness, sweating, confusion, or rapid heartbeat
Normally priced at $249-$300 per month, you can get started for as little as $149
US$ 25.87
US$ 21.15
US$ 26.91
US$ 27.27
US$ 27.58
